Among some examples, we should highlight the impact of endocrine therapy for ER+ tumours using aromatase inhibitors or tamoxifen, or the antibody herceptin/trastuzumab for tumours showing HER2+ overexpression [14]. Here, ERBB2 is linked to neoplasm.